ACEA/ ARACHIDONYL-2'-CHLOROETHYLAMIDE - synthetic, CB1 agonist studies completed

Overview
Arachidonyl-2'-chloroethylamide (ACEA) is a synthetic agonist of the cannabinoid receptor 1 (CB1R). ACEA is considered to be a selective cannabinoid agonist as it binds primarily to the CB1R and has low affinity to the cannabinoid receptor 2 (CB2R) (Ki = 1.4 nM for CB1R; Ki = 3100 nM for CB2R).

ACEA / Science & Research Articles

Neurotoxicology.

Neuropsychopharmacology.

Neuroscience Letter.

Epilepsy Research.

2011 - Study ~ L-Type Calcium Channel Mediates Anticonvulsant Effect of Cannabinoids in Acute and Chronic Murine Models of Seizure.
Neurochemical Research.

Phytochemistry.

Neuropsychopharmacology.

Physiology & Behavior.

Neuropsychopharmacology and Biological Psychiatry.

Parmazie.

Epilepsy Research.

Journal of the International League Against Epilepsy.

British Journal of Pharmacology.

Neuropsychopharmacology.

American College of Rheumatology.

Journal of Neurophysiology.

Molecular Pharmacology.

Neuropsychopharmacology.

2007 - Study ~ Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis:
Journal of Pharmacology and Experimental Therapeutics.

Neuroscience Letter.

Institute of Pharmacology Polish Academy of Sciences.

Neuroscience Letter.


Oops! This site has expired.

If you are the site owner, please renew your premium subscription or contact support.